Dear Daysoft Contact Lens Wearer
I hope that you find the information on this BLOG
to be of interest to you. It includes some personal
details and some information about the company.
However, perhaps the most important thing to say is
that whoever comes in contact with Daysoft ... as a
customer or not ... should feel that they have been
treated courteously and honestly at all times.
We are proud to be manufacturing our lenses in the UK
and to be selling millions every month to Independent Opticians, European
Optical Multiples (using their own-brand names) and, increasingly, on-line via our
website www.daysoft.com
Kind regards from the Daysoft Team
Ron, Founder & Executive Chairman.
PS Why not take a moment to read over 8,000 Wearer Reviews on
http://about.daysoftcontactlenses.com/Wearer-Comments.aspx
A little bit of personal history! I led the invention & development of the the world's first daily disposable contact lens business before selling it to Bausch & Lomb in 1996. The subsequent market entry by J&J (Acuvue) and by CIBA (Focus Dailies) should have driven cost down to an affordable level but this did not happen thereby depriving millions of contact lens wearers of the benefits of daily disposability. Therefore, on the expiry of my 5 year non-compete agreement, in 2001, I completed a new lens design and production process and launched daysoft with the goal of replacing all other brands but at a uniquely low cost to wearers. This was the birth of Daysoft Limited.
In the Daysoft Group Lab in Scotland we design our lenses, the equipment to make them on and we are proud to sell millions every month around the world through both Opticians and on-line. We rely on advanced production technology and the rapidly emerging Internet technologies and are pleased to see daysoft being marketed for just £12.48/month delivered to your home or office.
daysoft limited now has data on file relating to over12 million brand comparisons and extensive wearer feedback.
The claim that daysoft replaces other brands for half the price is justifiable.
I hope you will have time to read the Journal entries and the other articles shown opposite, in particular:
*Solution are the problem *Solution infections